The goal of this paper is to evaluate the data in favour of epinephrine as the first line of anaphylaxis therapy, rather than H-1 antihistamines or corticosteroids. The goal of this review is to determine if epinephrine has a rapid start of action and antagonises various mediators involved in anaphylaxis. Within 10 minutes of intramuscular injection into the thigh, epinephrine has a maximum pharmacodynamic impact. Prefilled epinephrine auto-injectors are accessible due to the short therapeutic window of epinephrine. With auto-injectors prefilled with 0.15, 0.30, and 0.50 mg of epinephrine, weight-appropriate dosages are available. Furthermore, needle lengths range from 1.17 to 2.50 cm. To guarantee intramuscular administration in the thigh, several dosages and needle lengths are offered for paediatric and adult patients, particularly obese individuals.
Fatalities have occurred as a result of failure to give epinephrine quickly. Patients and caregivers must be educated about anaphylaxis and get early treatment.
